The effect of low-dose interferon treatment on visual evoked potentials. 1997

M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
University Eye Clinic of Athens, Greece.

Patients suffering from chronic viral hepatitis, treated with interferon alpha-2b in a dose of 3 million units trice weekly subcutaneously, were studied. The influence of interferon on the optic nerve was evaluated by measuring the P100 implicit time of the visual evoked potentials. The results before the treatment were compared with those after 6 and 12 months of therapy, as well as with those of normal subjects. There were statistically significant differences between the groups. Furthermore, in 10 of 56 eyes (17.8%) after 6 months of treatment, and 8 of 22 eyes (36.3%) after 12 months of treatment, the P100 was abnormally delayed. The long term neurovisual effects of low-dose interferon are currently under investigation.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009900 Optic Nerve The 2nd cranial nerve which conveys visual information from the RETINA to the brain. The nerve carries the axons of the RETINAL GANGLION CELLS which sort at the OPTIC CHIASM and continue via the OPTIC TRACTS to the brain. The largest projection is to the lateral geniculate nuclei; other targets include the SUPERIOR COLLICULI and the SUPRACHIASMATIC NUCLEI. Though known as the second cranial nerve, it is considered part of the CENTRAL NERVOUS SYSTEM. Cranial Nerve II,Second Cranial Nerve,Nervus Opticus,Cranial Nerve, Second,Cranial Nerves, Second,Nerve, Optic,Nerve, Second Cranial,Nerves, Optic,Nerves, Second Cranial,Optic Nerves,Second Cranial Nerves
D009902 Optic Neuritis Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis). Neuropapillitis,Retrobulbar Neuritis,Anterior Optic Neuritis,Posterior Optic Neuritis,Anterior Optic Neuritides,Neuritides, Anterior Optic,Neuritides, Optic,Neuritides, Posterior Optic,Neuritides, Retrobulbar,Neuritis, Anterior Optic,Neuritis, Optic,Neuritis, Posterior Optic,Neuritis, Retrobulbar,Neuropapillitides,Optic Neuritides,Optic Neuritides, Anterior,Optic Neuritides, Posterior,Optic Neuritis, Anterior,Optic Neuritis, Posterior,Posterior Optic Neuritides,Retrobulbar Neuritides
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005074 Evoked Potentials, Visual The electric response evoked in the cerebral cortex by visual stimulation or stimulation of the visual pathways. Visual Evoked Response,Evoked Potential, Visual,Evoked Response, Visual,Evoked Responses, Visual,Potential, Visual Evoked,Potentials, Visual Evoked,Response, Visual Evoked,Responses, Visual Evoked,Visual Evoked Potential,Visual Evoked Potentials,Visual Evoked Responses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
March 1986, Bulletin des societes d'ophtalmologie de France,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
August 1974, Perceptual and motor skills,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
January 2000, Vojnosanitetski pregled,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
January 1993, Psychopharmacology,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
January 1981, Alcoholism, clinical and experimental research,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
November 1980, Electroencephalography and clinical neurophysiology,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
January 2011, Neurotoxicology and teratology,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
November 2002, The International journal of neuroscience,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
January 2009, The International journal of neuroscience,
M Moschos, and E Manesis, and E Panagakis, and D Brouzas, and S Hadziyannis, and G Theodossiadis
January 1986, Neurologia i neurochirurgia polska,
Copied contents to your clipboard!